Centessa Pharmaceuticals PLC

Centessa Pharmaceuticals Plc is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. Its portfolio consists of preclinical to phase three uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. The firm products include Vasopressin V2 Receptor Inhibitor (Lixivaptan), BMP9 Engineered Variant (MGX292), OX2R Agonist (Oral) among others. The company was founded on October 26, 2020 and is headquartered in Altrincham, the United Kingdom.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. Its portfolio include preclinical to phase three uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. The company was founded on October 26, 2020 and is headquartered in Altrincham, the United Kingdom.

~ Successful completion of an initial public offering of American Depositary Shares raising gross proceeds of $379.5 million to help advance portfolio of 16 clinical and preclinical programs ~

Centessa Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Updates

If two heads are better than one, consider what 10 can accomplish. That's the thinking behind Centessa Pharmaceuticals ( CNTA , Financial), a company constructed from the merger of 10 small drug companies.

Centessa Hits the Market in 3rd Biggest Biotech IPO of the Year

If two heads are better than one, consider what ten can accomplish.

Centessa Hits the Market in Third Biggest Biotech IPO of the Year

CAMBRIDGE, Mass. and LONDON, June 07, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an analyst-led fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021, beginning at 5:30 p.m. Eastern Time.

Centessa Pharmaceuticals to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

CAMBRIDGE, Mass. and LONDON, June 04, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Centessa”), a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, announced today that, in connection with its previously announced initial public offering of 16,500,000 American Depositary Shares (“ADSs”), the underwriters have fully exercised their option to purchase an additional 2,475,000 ADSs at the initial public offering price of $20.00 per ADS, less underwriting discounts and commissions. The closing of the initial public offering occurred on June 2, 2021 and the issuance and sale of the additional ADSs closed today. The gross proceeds to Centessa from its initial public offering, before deducting underwriting discounts, commissions and other estimated offering expenses, totaled an aggregate of $379.5 million.

Centessa Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs

Day One Biopharmaceuticals

Dynamics Special Purpose Corp

FIGS

Flywire Corp

Fifth Wall Acquisition Corp III

Singular Genomics Systems

Paymentus Holdings

Uber

ZipRecruiter

Zoom Video

Six IPOs raised $1.8 billion ahead of the short holiday week, joined by one direct listing and five SPACs. Returns bounced back after tumultuous trading earlier this month, with the week's deals all finishing above issue.

U.S. IPO Weekly Recap And Week Ahead

CAMBRIDGE, Mass. & LONDON--(BUSINESS WIRE)--Centessa Announces Pricing of Initial Public Offering

Centessa Announces Pricing of Initial Public Offering

ZipRecruiter, the fourth company this year to go ahead with a direct listing, is leading a slate of seven companies to the public equity markets this week.

ZipRecruiter, Another Direct Listing, Is One of Seven IPOs This Week

News for Centessa Pharmaceuticals PLC Stock (CNTA)